{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016068","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.181238+00:00","generated_at":"2026-06-24T02:15:47.165472+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Janux Therapeutics reports Q2 net loss of $16.9M; IND cleared for lead candidate JANX007","bullets":["Net loss $16.9M vs $6.2M in Q2 2021; R&D expenses rose to $14.1M from $4.7M.","Cash and short-term investments $354.3M (Dec 31, 2021: $375.0M).","FDA cleared IND for JANX007 (PSMA-TRACTr) for mCRPC; Phase 1 trial expected 2H 2022.","IND submission for JANX008 (EGFR-TRACTr) on track for 2H 2022; TROP2-TRACTr IND planned for 2023.","First TRACIr candidate (PD-L1xCD28) IND-enabling studies ongoing; IND submission expected 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016068","json":"https://secwatch.observer/filing/0000950170-22-016068.json","markdown":"https://secwatch.observer/filing/0000950170-22-016068.md","text":"https://secwatch.observer/filing/0000950170-22-016068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017022016068/0000950170-22-016068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017022016068/janx-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:15:47.165472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}